Sofinnova Partners has closed its latest flagship fund, Sofinnova Capital XI, at €650 million, surpassing its original target and marking one of the firm’s most significant raises to date. The close brings Sofinnova’s total capital raised across its platform to €1.5 billion over the past year, reinforcing its position as one of Europe’s leading life sciences venture capital firms.
The firm, headquartered in Paris with offices in London and Milan, will deploy Capital XI into early-stage biopharmaceutical and medical technology companies across Europe and the United States. The strategy continues Sofinnova’s long-standing focus on backing startups developing novel therapies and clinical innovations aimed at areas of significant unmet medical need. The fund is already active and has begun making initial investments in select portfolio companies, with further allocations planned for both new and follow-on financing rounds.
Capital XI drew substantial interest from global blue-chip institutional investors, including sovereign wealth funds, major pharmaceutical groups, insurance firms, foundations, corporates, and family offices. Commitments came from Europe, North America, Asia, and the Middle East, with a majority of returning limited partners and a meaningful influx of new world-class investors. The diverse LP base reflects sustained confidence in Sofinnova’s track record and its multi-strategy platform, which is supported by a seasoned team of partners including Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
The firm, founded in 1972, now manages over €4 billion in assets and has backed more than 500 companies globally over five decades. With Capital XI, Sofinnova aims to strengthen its commitment to company creation and early-stage scientific innovation, continuing its role as a hands-on investor throughout the life sciences value chain.
KEY QUOTES
“This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.”
“Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.”
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners
